Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An opportunity for pharmacists

Am J Health Syst Pharm. 2022 Jan 1;79(1):e65-e70. doi: 10.1093/ajhp/zxab271.

¹ College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
² Primary Care Department, Touro University, Vallejo, CA, USA.
³ National Kidney Foundation, New York, NY, USA.
⁴ Providence Medical Research Center, Providence Health Care, Spokane, WA, and Division of Medicine, University of Washington, Spokane and Seattle, WA, USA.
⁵ Providence Medical Research Center, Providence Health Care, Spokane, WA, and Division of Nephrology, Kidney Research Institute, University of Washington, Spokane and Seattle, WA, USA.

No abstract available

Keywords: SGLT2 inhibitor; diabetic kidney disease; kidney outcomes; multidisciplinary care; pharmacist intervention.

MeSH terms